Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes

Journal of Proteomics

Volumn 92, Issue , 2013, Pages 313-322

  Gradinaru, Daniela ^a,b   Borsa, Claudia ^a   Ionescu, Cristina ^a   Margina, Denisa ^b  

^a National Institute of Gerontology and Geriatrics   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Advanced glycation end products (AGEs); Advanced oxidation protein products (AOPPs); Elderly; Oxidative stress; Prediabetes; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; SYNTHESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADVANCED GLYCATION END PRODUCTS (AGES); ADVANCED OXIDATION PROTEIN PRODUCTS (AOPPS); ELDERLY; OXIDATIVE STRESS; PREDIABETES; TYPE 2 DIABETES;

AGED; AGING; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 84886952382     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.03.034     Document Type: Article

References (62)

1. Lyons T.J., Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res 2012, 159:303-312.
2. Prasad A., Bekker P., Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol Rev 2012, 20:177-183.
3. Beisswenger P.J. Glycation and biomarkers of vascular complications of diabetes. Amino Acids 2012, 42:1171-1183.
4. Jaisson S., Gillery P. Evaluation of nonenzymatic posttranslational modification derived products as biomarkers of molecular aging of proteins. Clin Chem 2010, 56:1401-1412.
5. Ghosh S., Lertwattanarak R., Lefort N., Molina-Carrion M., Joya-Galeana J., Bowen B.P., et al. Reduction in reactive oxygen species production by mitochondria from elderly subjects with normal and impaired glucose tolerance. Diabetes 2011, 60:2051-2060.
6. Herder C., Karakas M., Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. J Clin Pharm Ther 2011, 90:52-66.
7. Aslan D. Biomarkers for diabetes complications: the results of several clinical studies. J Med Biochem 2011, 30:207-212.
8. Yang H., Jin X., Lam C.W.K., Yan S.K. Oxidative stress and diabetes mellitus. Clin Chem Lab Med 2011, 49:1773-1782.
9. Padrão I.A., Ferreira R., Vitorino R., Amado F. Proteome-base biomarkers in diabetes mellitus: progress on biofluids' protein profiling using mass spectrometry. Proteomics Clin Appl 2012, 6:447-466.
10. Siwya J., Vlahoub A., Zimmerlic L.U., Zürbiga P., Schiffer E. Clinical proteomics: current techniques and potential applications in the elderly. Maturitas 2011, 68:233-244.
11. Gjesing A.P., Pedersen O. 'Omics'-driven discoveries in prevention and treatment of type 2 diabetes. Eur J Clin Invest 2012, 42:579-588.
12. Kalousová M., Škrha J., Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002, 51:597-604.
13. Abou-Seif M.A., Youssef A.A. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004, 346:161-170.
14. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
15. Tabak O., Gelisgen R., Erman H., Erdenen F., Muderrisoglu C., Aral H., et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med 2011, 34:E163-E171.
16. Piwowar A., Knapik-Kordecka M., Warwas M. Markers of oxidative protein damage in plasma and urine of type 2 diabetic patients. Br J Biomed Sci 2009, 66:194-199.
17. Barsotti A., Fabbi P., Fedele M., Garibaldi S., Balbi M., Bezante G.P., et al. Role of advanced oxidation protein products and Thiol ratio in patients with acute coronary syndromes. Clin Biochem 2011, 44:605-611.
18. Simm A., Wagner J., Gursinsky T., Nass N., Friedrich I., Schinzel R., et al. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?. Exp Gerontol 2007, 42:668-675.
19. Meerwaldt R., Links T., Zeebregts C., Tio R., Hillebrands J.L., Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008, 7:29.
20. Bansal S., Chawla D., Siddarth M., Banerjee B.D., Madhu S.V., Tripathi A.K. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin Biochem 2013, 46:109-114.
21. Chang J.B., Chu N.F., Syu J.T., Hsieh A.T., Hung Y.R. Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients. Lipids Health Dis 2011, 10:228.
22. Pitocco D., Zaccardi F., Di Stasio E., Romitelli F., Santini S.A., Zuppi C., et al. Oxidative stress, nitric oxide, and diabetes. Rev Diab Stud 2010, 1:15-25.
23. Ghasemi A., Zahediasl S., Azimzadeh I., Azizi F. Increased serum nitric oxide metabolites in dysglycaemia. Ann Hum Biol 2011, 38:577-582.
24. Sarangi R., Padhi S., Mahapatra S., Bhumika N. Serum nitric oxide metabolites and high sensitivity C-reactive protein are important biomarkers in non obese, Indian type 2 diabetic males. Int J Diab Develop Countr 2012, 32:163-168.
25. DeFronzo R.A., Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011, 108:3B-24B.
26. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34:562-569.
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
28. Maruyama C., Imamura K., Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003, 10:186-191.
29. Boizel R., Benhamou P.Y., Lardy B., Laporte F., Foulon T., Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000, 23:1679-1685.
30. Wieland H., Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res 1983, 24:904-909.
31. Scoccia A.E., Molinuevo M.S., McCarthy A.D., Cortizo A.M. A simple method to assess the oxidative susceptibility of low density lipoproteins. BMC Clin Pathol 2001, 1:1.
32. Bartling B., Hofmann H.S., Sohst A., Hatzky Y., Somoza V., Silber R.E., et al. Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end-products in non-small cell lung carcinoma. Mol Med 2011, 17:980-989.
33. Tatsch E., Bochi G.V., Pereira R.S., Kober H., Oliveira J.R., Moresco R.N. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clin Biochem 2011, 44:348-350.
34. Roriz-Filhon J.S., Sá-Roriz T.M., Rosset I., Camozzato A.L., Santos A.C., Chaves M.F., Moriguti JC, Roriz-Cruz M. (Pre-diabetes, brain aging, and cognition. Biochim Biophys Acta Mol Basis Dis 2009, 1792:432-443.
35. Tabák A.G., Herder C., Rathmann W., Brunner E.J., Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012, 379:2279-2290.
36. Hollander P., Spellman C. Controversies in prediabetes: do we have a diagnosis?. Postgrad Med 2012, 124:109-118.
37. Kurihara O., Takano M., Yamamoto M., Shirakabe A., Kimata N., Inami T., et al. Impact of prediabetic status on coronary atherosclerosis: a multivessel angioscopic study. Diab Care 2013, 36:729-733.
38. Shin J.Y., Lee H.R., Lee D.C. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol 2011, 10:30.
39. Gradinaru D., Borsa C., Ionescu C., Margina D., Prada G.I., Jansen E. Vitamin D status and oxidative stress markers in elderly with impaired fasting glucose and type 2 diabetes mellitus. Aging Clin Exp Res 2012 Sep 10, [Epub ahead of print].
40. Paik J.K., Kim M., Kwak J.H., Lee E., Lee S.H., Lee J.H. Increased arterial stiffness in subjects with impaired fasting glucose. J Diab Compl 2012 Nov 22, [Epub ahead of print].
41. Borsa C., Ionescu C., Gradinaru D. Oxidized LDL and NO synthesis as biomarkers of atherogenesis. Correlations with metabolic profile in elderly. Atherogenesis 2011, 473-494. InTech Open Access Publisher, [Available at: http://www.intechopen.com/articles/show/title/oxidized-ldl-and-no-synthesis-as-biomarkers-of-atherogenesis-correlations-with-metabolic-profile-in]. S. Parthasarathy (Ed.).
42. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495e506.
43. Lopes-Virella M.F., Hunt K.J., Baker N.L., Lachin J., Nathan D.M., Virella G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011, 60:582-589.
44. Brownlee M., Vlassara H., Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985, 34:938-941.
45. Wong R.K., Pettit A.I., Quinn P.A., Jennings S.C., Davies J.E., Ng L.L. Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic acid. Circulation 2003, 108:1858-1864.
46. Tan K.C., Chow W.S., Ai V.H., Metz C., Bucala R., Lam K.S. Advanced glycation end-products and endothelial dysfunction in type 2 diabetes. Diab Care 2002, 25:1055-1059.
47. Xu B., Chibber R., Ruggerio D., Kohner E., Ritter J., Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation endproducts. FASEB J 2003, 17:1289-1291.
48. Witko-Sarsat V., Nguyen-Khoa T., Jungers P., Drucke T.B., Deschamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uremia. Nephrol Dial Transplant 1999, 14:76-78.
49. Drueke T.B., Massy Z.A. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 2002, 20:494-497.
50. Kalousova M., Zima T., Tesar V., Dusilova-Sulkova S., Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005, 579:37-46.
51. Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol Res 2010, 59:147-156.
52. Aldini G., Dalle-Donne I., Facino R.M., Milzani A., Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med Res Rev 2007, 27:817-868.
53. Cannizzo E.S., Clement C.C., Sahu R., Follo C., Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics 2011, 74:2313-2323.
54. Negre-Salvayre A., Auge N., Ayala V., Basaga H., Boada J., Brenke R., et al. Pathological aspects of lipid peroxidation. Free Radic Res 2010, 44:1125-1171.
55. Selmeci L. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome?. Free Rad Res 2011, 45:1115-1123.
56. Marsche G., Frank S., Hrzenjak A., Holzer M., Dirnberger S., Wadsack C., et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009, 104:750-757.
57. Lapolla A., Porcu S., Traldi P. Some views on proteomics in diabetes. Clin Chem Lab Med 2011, 49:943-957.
58. Schindhelm R.K., Alssema M., Scheffer P.G., Diamant M., Dekker J.M., Barto R., et al. Fasting and postprandial glycoxidative and lipoxidative stress are increased in women with type 2 diabetes. Diabetes Care 2007, 30:1789-1794.
59. Krajčovičová-Kudláčková M., Ebeková K., Schinzel R., Klvanová J. Advanced glycation end products and nutrition. Physiol Res 2002, 51:6-313.
60. Rybka J., Kupczyk D., Kedziora-Kornatowska K., Motyl J., Czuczejko J., Szewczyk-Golec K., et al. Glutathione-related antioxidant defense system in elderly patients treated for hypertension. Cardiovasc Toxicol 2011, 1:1-9.
61. Hartog J.W., van de Wal R.M., Schalkwijk C.G., Miyata T., Jaarsma W., Plokker H.W., et al. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur J Heart Fail 2010, 12:397-403.
62. Esteghamati A., Eskandari D., Mirmiranpour H., Noshad S., Mousavizadeh M., Hedayati M., et al. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr 2012 Aug 21, [Epub ahead of print].